# Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

> **NCT04201808** · PHASE4 · UNKNOWN · sponsor: **New Discovery LLC** · enrollment: 100 (estimated)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Tenofovir Alafenamide 25 MG

## Key facts

- **NCT ID:** NCT04201808
- **Lead sponsor:** New Discovery LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04201808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04201808, "Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04201808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*